<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Inst of Molecular &amp; Cellular Biology</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6E92AB00-B415-45E5-A66A-3D8E61FDA1A5"><gtr:id>6E92AB00-B415-45E5-A66A-3D8E61FDA1A5</gtr:id><gtr:firstName>MPG</gtr:firstName><gtr:surname>Harris</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0401577"><gtr:id>B83A8889-152F-41C3-909C-5FE354D95CDF</gtr:id><gtr:title>Perturbation of Ras-Erk and phosphatidylinositol 3-kinase signalling pathways by the hepatitis C virus NS5A protein</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401577</gtr:grantReference><gtr:abstractText>The World Health Organisation estimates that 170 million individuals are infected with the hepatitis C virus,with 3-4 million new cases occurring each year. Hepatitis is a disease of the liver, a very important organ in the body. The virus manages to survive in liver cells for many years before leading to disease which can result both in liver failure and liver cancer. Although there are treatments for the infection, they do not always work and often have unpleasant side effects ? new and better drugs are urgently needed. This research aims to discover how one of the components of the virus, a protein called NS5A, works to alter the function of liver cells that are infected with the virus, both to ensure virus survival and contribute to the disease caused by the virus. This is important becauseif we can understand how this protein works then we may be able to devise new chemicals that prevent its function ? these could have potential as new drugs to treat patients who have hepatitis C virus infection.</gtr:abstractText><gtr:technicalSummary>My laboratory has previously shown that, whereas hepatitis C virus NS5A blocks signalling through the Ras-Erk MAP kinase pathway, it activates signalling via the phosphatidylinositol 3-kinase (PI3K) pathway. These data are consistent with a coordinated perturbation of cell physiology by NS5A, blocking Ras-Erk signalling will result in cell cycle arrest in the G1 phase and induction of apoptosis, the latter will be countered by the activation of PI3K which will provide the signals necessary for survival of infected cells. I propose a comprehensive and in-depth analysis to further investigate these effects with respect to both molecular mechanisms and functional consequences for the cell and virus. These studies will exploit the extensive panel of reagents, experimental systems and associated expertise built up in my laboratory over the past 5 years. In addition to providing new insights into the pathogenesis of HCV, I expect them to pave the way for the development of novel antivirals targeted to NS5A.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-23</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-24</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>414134</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Arrow Therapeutics</gtr:department><gtr:description>CASE award</gtr:description><gtr:id>B52DF27E-5335-4075-9933-88A1FEE6A3BA</gtr:id><gtr:impact>Two papers published by the CASE student (Mair Hughes)
Company now ceased trading</gtr:impact><gtr:partnerContribution>n/a</gtr:partnerContribution><gtr:piContribution>Supply of reagents and virological expertise</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>talks and posters</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>BFC6D41B-5878-4BD1-9A62-5F6FCBEF290B</gtr:id><gtr:impact>Talks and posters at a public understanding of science meeting held at the University of Leeds Also radio interview about hepatitis C virus given on Radio Leeds

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>7FE73A10-3D6D-4BD9-8D81-80850A2ECE5C</gtr:id><gtr:impact>Press release on PNAS paper

Interest from members of the public with HCV infection</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>48000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pump priming grant</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Yorkshire Cancer Research</gtr:fundingOrg><gtr:id>9FA09124-DFAB-4CFC-BBD4-808DF52F74AD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>280000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust project grant</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>A3D30BFE-1BCF-45CF-AB63-DB7EFA5035D8</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Hepatitis C Virus Therapy. Application number 0917046.5. That existing agonists of AMPK can be used to block HCV replication.</gtr:description><gtr:id>85E191B6-B231-471B-AD72-5AB20AE60898</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>GB0917046.5</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>AMPK agonists as HCV therapy</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We demonstrated that HCV NS5A blocks the activity of a pro-apoptotic ion channel - thus contributing to the persistence of the virus</gtr:description><gtr:id>9F3E6705-65B8-4462-9B1E-9BA9C6D83FE2</gtr:id><gtr:impact>PNAS paper</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Viral suppression of potassium channel</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8FEA43E0-3F47-4FA7-9E2B-1B1905745509"><gtr:id>8FEA43E0-3F47-4FA7-9E2B-1B1905745509</gtr:id><gtr:title>Suppression of a pro-apoptotic K+ channel as a mechanism for hepatitis C virus persistence.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24d87c50db64b39131deacbf06e2fe80"><gtr:id>24d87c50db64b39131deacbf06e2fe80</gtr:id><gtr:otherNames>Mankouri J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AE7F2F9E-4226-40EE-854C-21E55AD99567"><gtr:id>AE7F2F9E-4226-40EE-854C-21E55AD99567</gtr:id><gtr:title>Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24d87c50db64b39131deacbf06e2fe80"><gtr:id>24d87c50db64b39131deacbf06e2fe80</gtr:id><gtr:otherNames>Mankouri J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D7E4D009-F499-4092-9DC6-45D54EBF3A3E"><gtr:id>D7E4D009-F499-4092-9DC6-45D54EBF3A3E</gtr:id><gtr:title>A comparative cell biological analysis reveals only limited functional homology between the NS5A proteins of hepatitis C virus and GB virus B.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24d87c50db64b39131deacbf06e2fe80"><gtr:id>24d87c50db64b39131deacbf06e2fe80</gtr:id><gtr:otherNames>Mankouri J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C796C71B-13B1-4053-AABF-85742B9996CA"><gtr:id>C796C71B-13B1-4053-AABF-85742B9996CA</gtr:id><gtr:title>Hepatitis C virus NS5A protein interacts with beta-catenin and stimulates its transcriptional activity in a phosphoinositide-3 kinase-dependent fashion.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1bd4efc801c86be0dbb05d734320767f"><gtr:id>1bd4efc801c86be0dbb05d734320767f</gtr:id><gtr:otherNames>Milward A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8D76142F-E0FA-49A2-8802-959BFFF04D17"><gtr:id>8D76142F-E0FA-49A2-8802-959BFFF04D17</gtr:id><gtr:title>A conserved proline between domains II and III of hepatitis C virus NS5A influences both RNA replication and virus assembly.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/61f0cf0f16d76c3fe54012bce667060a"><gtr:id>61f0cf0f16d76c3fe54012bce667060a</gtr:id><gtr:otherNames>Hughes M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/69EB1DCB-8862-420D-83EE-A91E185CE120"><gtr:id>69EB1DCB-8862-420D-83EE-A91E185CE120</gtr:id><gtr:title>Optineurin negatively regulates the induction of IFNbeta in response to RNA virus infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24d87c50db64b39131deacbf06e2fe80"><gtr:id>24d87c50db64b39131deacbf06e2fe80</gtr:id><gtr:otherNames>Mankouri J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB75C973-B5AE-48C0-865B-85A07E1E7EB0"><gtr:id>AB75C973-B5AE-48C0-865B-85A07E1E7EB0</gtr:id><gtr:title>Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/61f0cf0f16d76c3fe54012bce667060a"><gtr:id>61f0cf0f16d76c3fe54012bce667060a</gtr:id><gtr:otherNames>Hughes M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CFB96740-DFD9-459A-8C45-C9F7D5BAFA7E"><gtr:id>CFB96740-DFD9-459A-8C45-C9F7D5BAFA7E</gtr:id><gtr:title>Hepatitis C virus RNA replication is regulated by Ras-Erk signalling.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/80ba78193a25dff51ba8ee2d4ff274d1"><gtr:id>80ba78193a25dff51ba8ee2d4ff274d1</gtr:id><gtr:otherNames>Gretton S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1E39A2AD-2CEA-45DB-A230-7C6CAB461250"><gtr:id>1E39A2AD-2CEA-45DB-A230-7C6CAB461250</gtr:id><gtr:title>The hepatitis C virus non-structural protein NS5A alters the trafficking profile of the epidermal growth factor receptor.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24d87c50db64b39131deacbf06e2fe80"><gtr:id>24d87c50db64b39131deacbf06e2fe80</gtr:id><gtr:otherNames>Mankouri J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401577</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>